Bausch Health Companies Inc. (BHC): Price and Financial Metrics
Bausch Health Companies Inc. (BHC)
Today's Latest Price: $19.53 USD
Updated Nov 27 5:00pm
Add BHC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BHC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for BHC is 13.69 -- better than 97.78% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 45.26 for Bausch Health Companies Inc; that's greater than it is for 99.17% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Bausch Health Companies Inc is reporting a growth rate of -155.52%; that's higher than only 12.81% of US stocks.
- Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are KFS, ATLC, HCHC, SEAS, and KODK.
- BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to www.bauschhealth.com.
BHC Stock Price Chart Interactive Chart >
BHC Price/Volume Stats
| Current price | $19.53 | 52-week high | $31.97 |
| Prev. close | $19.17 | 52-week low | $11.15 |
| Day low | $19.23 | Volume | 1,033,373 |
| Day high | $19.64 | Avg. volume | 4,830,948 |
| 50-day MA | $17.43 | Dividend yield | N/A |
| 200-day MA | $17.88 | Market Cap | 6.94B |
Bausch Health Companies Inc. (BHC) Company Bio
Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $19.53 | $1.83 | -90% |
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Bausch Health Companies Inc, consider:
- Interest coverage, a measure of earnings relative to interest payments, is -0.3; that's higher than merely 19.82% of US stocks in the Healthcare sector that have positive free cash flow.
- The company's compound free cash flow growth rate over the past 5.69 years comes in at -0.17%; that's greater than merely 9.88% of US stocks we're applying DCF forecasting to.
- 22% of the company's capital comes from equity, which is greater than just 7.25% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -91% |
| 1% | -91% |
| 2% | -90% |
| 3% | -90% |
| 4% | -90% |
| 5% | -90% |
RGEN, COO, EW, TEVA, and QGEN can be thought of as valuation peers to BHC, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...